Circadian Rhythms and Homeostatic Sleep Drive and Their Effect on Reward and Cognitive Control Systems in Adolescents
University of Pittsburgh · with National Institute on Drug Abuse (NIDA) · NCT05336084
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 13–18 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 200
- US sites recruiting
- 1
- Study start
- March 4, 2022
- Record last updated
- April 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Adolescence is a time of heightened reward sensitivity and greater impulsivity. On top of this, many teenagers experience chronic sleep deprivation and misalignment of their circadian rhythms due to biological shifts in their sleep/wake patterns paired with early school start times, which may increase the risk for substance use (SU). However, what impact circadian rhythm and sleep disruption either together or independently have on the neuronal circuitry that controls reward and cognition, or if there are interventions that might help to modify these disruptions is unknown. Project 1 (P1), specifically examines homeostatic and circadian characteristics as mechanisms linking habitual sleep patterns, reward and cognitive control (at subjective, behavioral, and circuit levels), and longitudinal substance use risk.
Being studied: Ultradian sleep/wake protocol
Conditions: Sleep
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 13-18 years
- Currently enrolled in a traditional high-school (not cyber- or home-schooled) [school closures during the COVID-19 pandemic are an exception to this]
- Physically and psychiatrically healthy
- Provision of written informed consent and assent
Exclusion Criteria
- outside age range above
- have a history of alcohol, cannabis, or illicit drug use greater than weekly use in the past year
- have serious medical or neurological disorders, including history of seizures
- have serious psychiatric disorders (e.g. bipolar disorder and schizophrenia)
- taking antidepressants (SSRIs/SSNIs are OK) or medications known to impact sleep/wake function - some medications may be okay if willing and able to discontinue prior to and/or for laboratory procedures
- have sleep disorders other than insomnia or Delayed Sleep Phase Disorder
- have MRI contraindications (i.e., metal in the body; claustrophobia)
- first degree relative with bipolar disorder
- frequent headaches or migraines
- inability to swallow pills/capsules.
- pregnancy
- participants with observed Obstructive Sleep Apnea via Apnealink, as indicated by an Apnea Hypopnea Index (AHI) of greater than 5
- Less than 80 lbs. or a BMI of greater than 35
Recruiting US locations
Western Psychiatric Hospital
Pittsburgh, PA 15213
Site contact: Ronette Blake, MS · 412-443-3704 · blakerg2@upmc.edu
Study contacts (from the official record)
- Ronette Blake, MS · (412) 443-3704 · blakerg2@upmc.edu
- Sarah Aerni · 412-551-110 · aernise2@upmc.edu
Similar studies in Pennsylvania
All sleep studies in Pennsylvania →- RecruitingPhase 2/Phase 3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.
- Location
- Abington, PA + 32 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Wyomissing, PA + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Alkermes, Inc.
- Location
- Wyomissing, PA + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Philadelphia, PA + 41 other US sites
- Eligibility basics
- Ages 18–74